|4-(3-(4-氰基-3-(三氟甲基)苯基)-5,5-二甲基-4-氧代-2-硫代咪唑烷-1-基)-2-氟苯甲酰胺|CsnPharm

CAS No.: 1242137-16-1

N-desmethyl Enzalutamide Catalog No. CSN17614

Synonyms: N-desmethyl MDV 3100

N-Desmethyl enzalutamide is a major metabolite of Enzalutamide, Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述N-Desmethyl enzalutamide is a major metabolite of Enzalutamide, Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03016312	Prostatic Neoplasms, Castratio... more >>n-Resistant Collapse <<	Phase 3	Active, not recruiting	July 9, 2022	-
NCT02929576	Breast Cancer	Phase 3	Withdrawn(Further understandin... more >>g about the role of androgen signaling in TNBC was required) Collapse <<	-	United States, Kansas ... more >> Topeka, Kansas, United States, 66606 United States, Louisiana Metairie, Louisiana, United States, 70006 United States, New York Bronx, New York, United States, 10469 United States, Texas Houston, Texas, United States, 77030 United States, Washington Tacoma, Washington, United States, 98405 Wenatchee, Washington, United States, 98801 Collapse <<
NCT02007512	Breast Cancer	Phase 2	Active, not recruiting	March 29, 2019	-

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.2202 mL
- 11.1010 mL
- 22.2020 mL
- 5 mM
- 0.4440 mL
- 2.2202 mL
- 4.4404 mL
- 10 mM
- 0.2220 mL
- 1.1101 mL
- 2.2202 mL

技术信息

CAS号	1242137-16-1	储存条件	粉末 Keep in dark place,Inert atmosphere,Room temperature 液体 -20°C:3-6 月 -80°C:12月
分子式	C20H14F4N4O2S	运输	蓝冰
分子量	450.41	别名	N-desmethyl MDV 3100

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03016312	Prostatic Neoplasms, Castratio... more >>n-Resistant Collapse <<	Phase 3	Active, not recruiting	July 9, 2022	-
NCT02929576	Breast Cancer	Phase 3	Withdrawn(Further understandin... more >>g about the role of androgen signaling in TNBC was required) Collapse <<	-	United States, Kansas ... more >> Topeka, Kansas, United States, 66606 United States, Louisiana Metairie, Louisiana, United States, 70006 United States, New York Bronx, New York, United States, 10469 United States, Texas Houston, Texas, United States, 77030 United States, Washington Tacoma, Washington, United States, 98405 Wenatchee, Washington, United States, 98801 Collapse <<
NCT02007512	Breast Cancer	Phase 2	Active, not recruiting	March 29, 2019	-
NCT02528643	Advanced Hepatocellular Carcin... more >>oma Collapse <<	Phase 2	Active, not recruiting	May 2019	-
NCT02138162	Severe Hepatic Impairment ... more >> Normal Hepatic Function Collapse <<	Phase 1	Completed	-	Bulgaria ... more >> Comac Medical Ltd. Sofia, Bulgaria, 1612 Collapse <<
NCT02007512	-	-	Active, not recruiting	-	-
NCT02528643	-	-	Active, not recruiting	-	-
NCT02225093	Pharmacokinetics of Dextrometh... more >>orphan Pharmacokinetics of Caffeine Prostate Cancer Collapse <<	Phase 1	Completed	-	Moldova, Republic of ... more >> Arensia Chisinau, Moldova, Republic of, 2025 Collapse <<
NCT02215096	Cancer	Phase 1	Recruiting	December 2, 2019	United States, California ... more >> GSK Investigational Site Completed Duarte, California, United States, 91010 GSK Investigational Site Completed Los Angeles, California, United States, 90089 GSK Investigational Site Recruiting Los Angeles, California, United States, 90095 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com United States, District of Columbia GSK Investigational Site Recruiting Washington, District of Columbia, United States, 20007 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com United States, Michigan GSK Investigational Site Recruiting Detroit, Michigan, United States, 48201 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com United States, New York GSK Investigational Site Completed New York, New York, United States, 10016 United States, Texas GSK Investigational Site Recruiting Houston, Texas, United States, 77030 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com United States, Utah GSK Investigational Site Terminated Salt Lake City, Utah, United States, 84112-5550 United Kingdom GSK Investigational Site Recruiting London, United Kingdom, SE1 9RT Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com GSK Investigational Site Recruiting Sutton, United Kingdom, SM2 5PT Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Collapse <<

N-desmethyl Enzalutamide Catalog No. CSN17614

靶点选择性

请登录您的专属账户

确认信息